Dehradun pharma CDMO making tablets, capsules & injectables for India's top drugmakers and its own brands.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 6 | 6 | 11 | 10 | 10 | 10 | 11 | 11 |
| Reserves | 203 | 193 | 384 | 392 | 440 | 495 | 524 | 570 |
| Borrowings | 29 | 32 | 7 | 5 | 4 | 33 | 31 | 35 |
| Other Liabilities | 100 | 65 | 90 | 122 | 173 | 222 | 249 | 291 |
| Total Liabilities | 338 | 296 | 491 | 529 | 626 | 760 | 814 | 907 |
| AssetsFixed Assets | 70 | 96 | 91 | 109 | 179 | 223 | 217 | 213 |
| CWIP | 0 | 0 | 8 | 15 | 6 | 5 | 24 | 60 |
| Investments | 116 | 23 | 65 | 107 | 173 | 223 | 246 | 268 |
| Other Assets | 152 | 177 | 327 | 298 | 268 | 308 | 327 | 366 |
| Total Assets | 338 | 296 | 491 | 529 | 626 | 760 | 814 | 907 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 19 | 25 | 11 | 9 | 61 | 109 | 68 | 105 |
| Cash from Investing | -7 | -14 | -20 | -155 | -14 | -92 | -74 | -92 |
| Cash from Financing | -6 | -5 | 1 | 130 | -44 | -15 | 1 | -13 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 10 | 10 | 6 | -6 | -9 | 71 | 16 | 37 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (25.0×) and current (26.7×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 16.8% growth and a 25× exit, ₹844 only delivers your return if you pay ₹762. The price is currently baking in 19% growth.
EPS grows 16.8%/yr for 5 years, then fades to 6% over 2, exits at 25×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 16.8% | 36.89 |
| FY28 | 16.8% | 43.08 |
| FY29 | 16.8% | 50.32 |
| FY30 | 16.8% | 58.77 |
| FY31 | 16.8% | 68.65 |
| FY32 | 11.4% ·fade | 76.47 |
| FY33 | 6.0% ·fade | 81.06 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.